The treatment field of Multiple Myeloma continues to move forward as novel agents and treatment combinations expand. Whether you are standard risk patient or belong to high-risk group, treatment paradigms are getting better. We are talking to Dr. Mateos on Myeloma research and treatment modalities discussed and presented at the recently concluded American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.
In December 2017, the FDA approved a DNA altering medication that can reverse an inherited form of progressive blindness. Luxturna is a gene therapy which can treat a condition called Leber's Congenital Amaurosis (LCA) wherein people have inherited two faulty copies of the RPE65 gene. The therapy replaces those faulty genes with normal versions, thus erasing the mutations' harmful effects. A single injection in each eye has shown to be enough to improve lost vision. We are talking to the doctor couple, Dr. Jean Bennett of University of Pennsylvania and Dr. Albert M. Maguire of Childrens' Hospital of Philadelhia (CHOP), whose work for more than 25 years on congenital blindness led to this ground breaking FDA approval. Listen to learn about the novel therapy, details on treatment procedure and recovery.
Myeloma patients are definitely living longer. A decade ago the median survival was 3 to 4 years, while now it is in the range of 8 to 10 years. With all the new drugs and treatments that have been approved, it is possible to control the disease for a longer period of time. We talked to Dr. Shaji Kumar to explore the treatment potential of intervening early in the disease and also touch upon how personalized therapies can help in managing myeloma efficiently.
Dr. Shaji Kumar
For any of the talks dial-in to 718-664-6574 to participate and ask a question LIVE On-Air! Only 50 callers permitted at one time so HURRY!